Deal Watch: Alnylam/Dicerna Pact Addresses IP Questions Around Primary Hyperoxaluria Programs
The two RNAi firms cross-license IP from their PH programs, while also partnering on a rare liver disease candidate. GSK invests $250m in Vir and will help to advance its antibody candidates for COVID-19.
You may also be interested in...
Building on data first reported last December, lumasiran appears on pace for approval by the December 2020 action date, but Dicerna still may show its drug is best-in-class.
Japanese firm builds on existing alliance to gain most global rights to US company’s potential best-in-class drug for lymphoma and B-cell malignancies.
Plus: Lilly unveils Olumiant COVID-19 study, Samsung and Vir to collaborate on antibody, Korean industry asks for government assistance.